Bioeq’s Lucentis Biosimilar Is Given EU Go-Ahead
Launch Dates And Financial Terms Of A Marketing Deal With Teva Remain Under Wraps
Bioeq’s Ranivisio ranibizumab biosimilar has gained European Commission authorization for all innovator indications including wet AMD, the leading cause of blindness among over-65s.
